



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 3, 2023

BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

Dear Sirs,

Sub: Pfizer Limited - Additional details requested for Corporate Announcement filed on November 1, 2023 under Regulation 30 of SEBI (LODR) Regulations, 2015.

This is with reference to the captioned Corporate Announcement made by the Company on November 1, 2023 and your email dated November 2, 2023 requesting additional details on the same.

We would like to clarify that, in our view, the transaction referred to in our Corporate Announcement dated November 1, 2023 i.e., Agreement to Assign and Assume the Lease of MIDC Land and Sale of Building constructed on such Land for transferring and assigning Pfizer's unexpired leasehold rights in the land situated at Plot No. 16, Trans Thane Creek Industrial Area, Turbhe, Thane to Zoetis Pharmaceutical Research Private Limited, does not fall under the agreements identified in point 5 of section A of Part A of Schedule III to Regulation 30 of SEBI LODR 2015 which require disclosure of additional details as envisaged under the said Regulation 30 read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015.

However, as requested by BSE, additional details required to be disclosed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015, are enclosed as Annexure A.

Request you to please take the above on record.

Thanking you,

Yours truly,
For **Pfizer Limited**

Prajeet Nair
Director – Corporate Services & Company Secretary

Encl.: A/a

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051

CIN: [L24231MH1950PLC008311](#)
Email ID: contactus.india@pfizer.com
Website: www.pfizerltd.co.in

ANNEXURE A

Additional details pursuant to the SEBI LODR 2015 read with SEBI Circular no.
CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. no	Particulars	Details
1.	Name(s) of party with whom the agreement is entered	Zoetis Pharmaceutical Research Private Limited ("Zoetis")
2.	Purpose of entering into the agreement	Transfer and assignment of Company's unexpired leasehold rights in the MIDC land admeasuring approx. 82,000 sq. mtrs. situated at Plot No. 16, Trans Thane Creek Industrial Area, Turbhe, Thane ("Land") and sale of structures and buildings having total built-up area of approx. 16,494.33 sq. mtrs. constructed thereon ("Buildings") to Zoetis.
3.	Shareholding, if any, in the entity with whom the agreement is executed	NIL
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	<ul style="list-style-type: none"> • The Company's unexpired leasehold rights in the Land admeasuring approx. 82,000 sq. mtrs. situated at Plot No. 16 at Thane – TTC and ownership rights in the Buildings having total built-up area of approx. 16,494.33 sq. mtrs. constructed thereon, would be transferred / sold to Zoetis for a lumpsum consideration of Rs.264.40 Crores • The said sale/ transfer shall be subject to requisite approvals from concerned regulatory authorities, including the Maharashtra Industrial Development Corporation.
5.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	Zoetis is not related to any of the promoters/promoter group/ group companies in any manner
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	The Transaction does not fall under the purview of Related Party Transactions.
7.	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
8.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	Not Applicable
9.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s) a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable